07:00 , Apr 6, 2015 |  BC Week In Review  |  Company News

Hyperion Therapeutics Inc, Horizon Pharma deal

Last June, EMA accepted for review an MAA for Ravicti to treat UCD; Hyperion expects a decision from EMA’s CHMP in late 2015 or early 2016. Hyperion plans to submit an sNDA for Ravicti to...
01:06 , Mar 31, 2015 |  BC Extra  |  Company News

Horizon buying Hyperion for $1.1B

Horizon Pharma plc (NASDAQ:HZNP) will acquire rare disease company Hyperion Therapeutics Inc. (NASDAQ:HPTX) for $46 per share, or $1.1 billion in cash. The price represents an 8% premium to Hyperion's Friday close of $42.74. Horizon...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

Hyperion, Valeant Pharmaceuticals deal

Hyperion completed the acquisition of worldwide rights to Buphenyl sodium phenylbutyrate from Valeant's Ucyclyd Pharma Inc. subsidiary. The exercise price was $19 million. The subsidiary exercised its option to retain Ammonul for $32 million. After...
07:00 , May 13, 2013 |  BC Week In Review  |  Company News

Hyperion, Valeant Pharmaceuticals deal

Hyperion exercised its option under an amended 2007 deal with Valeant's Medicis Pharmaceutical Corp. subsidiary to acquire worldwide rights to Buphenyl sodium phenylbutyrate and Ammonul . Hyperion will pay $22 million up front to Valeant,...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Company News

Hyperion, Medicis deal

Hyperion acquired worldwide rights to Ravicti glycerol phenylbutyrate ( HPN-100 ) from Medicis' Ucyclyd Pharma Inc. subsidiary. The companies also amended a 2007 deal to give Hyperion an option to acquire worldwide rights to Buphenyl...
08:00 , Jan 3, 2011 |  BioCentury  |  Emerging Company Profile

Hyperion: Building a better mop

The only drug approved as a chronic treatment for urea cycle disorders requires high doses and has high sodium content, resulting in a risk of hypertension and reduced appetite. Hyperion Therapeutics Inc. believes its sodium-free...
08:00 , Nov 8, 2010 |  BC Week In Review  |  Clinical News

Glycerol phenylbutyrate: Phase III data

A 4-week, double-blind, placebo-controlled, crossover, North American Phase III trial in 45 patients showed that thrice-daily HPN-100 met the primary endpoint of non-inferiority to Buphenyl sodium phenylbutyrate in blood ammonia levels as measured by 24-hour...
08:00 , Nov 8, 2010 |  BioCentury  |  Finance

Regulatory milestones

Regulatory milestones Adventrx Pharmaceuticals Inc. (NYSE-A:ANX) lost $0.03 to $2.07 last week after resubmitting an NDA to FDA for Exelbine vinorelbine injectable emulsion to treat non-small cell lung cancer (NSCLC). The company said the submission...
22:55 , Nov 2, 2010 |  BC Extra  |  Clinical News

Hyperion's HPN-100 meets Phase III endpoint

Hyperion Therapeutics Inc. (South San Francisco, Calif.) said glycerol phenylbutyrate ( HPN-100 ) met the primary endpoint of non-inferiority to Buphenyl sodium phenylbutyrate in blood ammonia levels in a Phase III trial to treat urea...
07:00 , Oct 25, 2010 |  BC Week In Review  |  Clinical News

Glycerol phenylbutyrate regulatory update

FDA granted Fast Track designation for Hyperion's glycerol phenylbutyrate (HPN-100) as adjunctive therapy for the chronic management of urea cycle disorders (UCD). The pre-prodrug of phenylacetic acid is in Phase III testing for UCD, with...